Association between SNPs within MicroRNA Binding Sites and the Prognosis of Breast Cancer

Abstract Background: Single nucleotide polymorphisms (SNPs) within microRNA binding sites can affect the binding of microRNA to mRNA and regulate gene expression, thereby contributing to the prognosis of cancer. We performed this study to explore the association between SNPs within microRNA binding sites and the prognosis of breast cancer.Methods: We carried out a two-stage study including 2647 breast cancer patients, with a median follow-up of 68 months (range 0-159). In stage I, we genotyped 192 SNPs within microRNA binding sites using the Illumina Goldengate platform. In stage II, we validated SNPs significantly associated with breast cancer prognosis in another dataset using the TaqMan platform. Survival times was calculated, and Kaplan-Meier curves and Cox regression model were used to analyze survival of breast cancer patients with different genotypes.Results: We identified 8 SNPs significantly associated with breast cancer prognosis in stage I (P<0.05), and only rs10878441 was statistically significant in stage II (AA vs CC: adjusted HR=2.21, 95% CI: 1.11-4.42, P=0.024). We combined the data from stage I and stage II, and found that, compared with rs10878441 AA genotype, CC genotype was significantly associated with poor survival of breast cancer (HR=1.69, 95% CI: 1.18-2.42, P=0.004; adjusted HR=2.19, 95% CI: 1.30-3.70, P=0.003). Stratified analyses demonstrated that rs10878441 was related to breast cancer prognosis in grade II patients and lymph node-negative patients (P<0.05).Conclusions: The LRKK2 rs10878441 CC genotype is associated with poor prognosis of breast cancer in a Chinese population, and it could be used as a potential prognostic biomarker for breast cancer. Further studies are warranted.

Download Full-text

Association Study between SNPs within MicroRNA Binding Sites and the Prognosis of Breast Cancer

10.21203/rs.3.rs-24736/v1 ◽

2020 ◽

Author(s):

Liwen Zhang ◽

Lu Han ◽

Yubei Huang ◽

Ziwei Feng ◽

Xin Wang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Binding Sites ◽

Cox Regression ◽

Breast Cancer Prognosis ◽

Stage I ◽

Cancer Prognosis ◽

Stage Ii ◽

Breast Cancer Patients ◽

Survival Times

Abstract Background: Single nucleotide polymorphisms (SNPs) within microRNA binding sites can affect the binding of microRNA to mRNA and regulate gene expression, thereby contributing to the prognosis of cancer. We performed this study to explore the association between SNPs within microRNA binding sites and the prognosis of breast cancer.Methods: We carried out a two-stage study including 2647 breast cancer patients. In stage I, we genotyped 192 SNPs within microRNA binding sites using the Illumina Goldengate platform. In stage II, we validated SNPs significantly associated with breast cancer prognosis in another dataset using the TaqMan platform. Survival times was calculated, and Kaplan-Meier curves and Cox regression model were used to analyze survival of breast cancer patients with different genotypes.Results: We identified 8 SNPs significantly associated with breast cancer prognosis in stage I (P<0.05), and only rs10878441 was statistically significant in stage II (AA vs CC: adjusted HR=2.21, 95% CI: 1.11-4.42, P=0.024). We combined the data from stage I and stage II, and found that, compared with rs10878441 AA genotype, CC genotype was significantly associated with poor survival of breast cancer (HR=1.69, 95% CI: 1.18-2.42, P=0.004; adjusted HR=2.19, 95% CI: 1.30-3.70, P=0.003). Stratified analyses demonstrated that rs10878441 was related to breast cancer prognosis in grade II patients and lymph node-negative patients (P<0.05).Conclusions: The LRKK2 rs10878441 CC genotype is associated with poor prognosis of breast cancer in a Chinese population, and it could be used as a potential prognostic biomarker for breast cancer. Further studies are warranted.

Download Full-text

Differing from diseased stage in melanoma, the olfactory receptor gene OR56A4 is expressed

10.31219/osf.io/yz37x ◽

2021 ◽

Author(s):

Bronte Morse ◽

Kobi Decker

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Olfactory Receptor ◽

Receptor Gene ◽

Stage I ◽

Stage Ii ◽

Stage Iii ◽

Olfactory Receptor Gene ◽

Breast Cancer Patients ◽

Receptor Family

We have compared the global profiles of 100 tumors in Stage I, II and III with two independently releasedmicroarray datasets in order to understand their transcriptional behaviors accompanying a progression in breastcancer (1, 2). The olfactive receptor, family 56, subfamily A, member 4 OR56A4, was discovered to have beenone of the genes with the most varied expression when comparing initial tumors in stage I, stage II, and stageIII of breast cancer patients. In the stage III tumors, OR56A4 expression in comparison to the stage I tumorswas lower.

Download Full-text

Early-stage male breast cancer: A 10-year experience

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e11630 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e11630-e11630

Author(s):

N. Gercovich ◽

E. Gil Deza ◽

M. Russo ◽

C. Garcia Gerardi ◽

C. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Male Breast Cancer ◽

Ductal Carcinoma ◽

Early Stage ◽

Male Breast ◽

Stage I ◽

Stage Ii ◽

Breast Cancers ◽

Breast Cancer Patients

e11630 Introduction: Male breast cancer is very rare, representing only between 0.7% and 1% of all breast cancers, and only half of them are early stage cases. Objective: The present study has been designed with the aim of studying retrospectively the clinical onset and evolution of male invasive breast cancer patients (stages I and II) treated at IOHM between 1997 and 2008. Methods: The records of 3,000 breast cancer cases followed between 1997 and 2008 were searched, looking for male stage I and II breast cancer patients. A database was designed following the recommendations of the Directors of Surgical Pathology of the USA. The information registered encompassed: adjuvant treatments, recurrence date and date of final consultation or death. Results: Twelve pts were identified. Mean age (range)= 66 yo (50–89 yo). Tumoral type= Invasive Ductal Carcinoma 12 pt. Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%). Nottingham´s grade= Grade 2: 8 pt, Grade 3: 3 pt, N/A=1 pt. Stage= I= 6 pt, II=6 pt. ER (Positve= 9 pt, Negative=1 pt, N/A= 2 pt). PR (Positve= 8 pt, Negative= 2 pt, N/A=2 pt). Her2neu (0+= 3 pt, 1+= 3 pt, 2+= 2 pt, N/A= 4 pt). Surgery= Mastectomy= 11 pt, Lumpectomy 1= pt. Radiotherapy=5 pt. Adjuvance= No=2 pt, Hormonotherapy (HT)= 3 pt, Chemotherapy (CHT) = 3 pt, CHT+HT= 4 pt. Recurrence= Yes= 2 pt, No= 10 pt. Survival: Dead= 1 pt, Alive =11 pt. Mean Time To Progression= Stage I =66 months, Stage II =42 months. Global survival: Stage I =66 months, Stage II =52 months. Conclusions: 1. Twelve stage I and II male breast cancer patients were identified out of 3000 (0.4%) breast cancer cases diagnosed and followed in the past 10 years at the IOHM. 2. Mastectomy was the surgical procedure in 11 of the 12 cases 3. Ten pt underwent adjuvant treatment. 4. With a mean follow up time of 60 months, all stage I patients are alive and there were no recurrences. Two of the 6 stage II pts progressed and one died. No significant financial relationships to disclose.

Download Full-text

Perceived Partner Adaptation and Psychosocial Outcomes for Newly Diagnosed Stage I and Stage II Breast Cancer Patients

Journal of Psychosocial Oncology ◽

10.1080/07347330802614774 ◽

2009 ◽

Vol 27 (1) ◽

pp. 42-58 ◽

Cited By ~ 17

Author(s):

Eugene Brusilovskiy ◽

Meredith Mitstifer ◽

Mark S. Salzer

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Psychosocial Outcomes ◽

Stage I ◽

Stage Ii ◽

Newly Diagnosed ◽

Breast Cancer Patients

Download Full-text

Influence of Smoking History on Breast Cancer Prognosis: Retrospective Study of 240 Operable Breast Cancer Patients Who Received Adjuvant Cyclophosphamide, Doxorubicin, and 5-Fluorouracil Chemotherapy Regimen

The Breast Journal ◽

10.1111/j.1524-4741.2007.00459.x ◽

2007 ◽

Vol 13 (4) ◽

pp. 431-432 ◽

Cited By ~ 6

Author(s):

Sercan Aksoy ◽

Hakan Harputluoglu ◽

Nilufer Guler ◽

Kadri Altundag ◽

Mutlu Hayran ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Cancer Patients ◽

Chemotherapy Regimen ◽

Operable Breast Cancer ◽

Breast Cancer Prognosis ◽

Cancer Prognosis ◽

Smoking History ◽

Breast Cancer Patients

Download Full-text

Exploratory Data Analysis on Breast Cancer Prognosis

Encyclopedia of Information Science and Technology, Fourth Edition ◽

10.4018/978-1-5225-2255-3.ch156 ◽

2018 ◽

pp. 1794-1805

Author(s):

Mohammad Mehdi Owrang O. ◽

Yasmine M. Kanaan ◽

Robert L. Copeland Jr. ◽

Melvin Gaskins ◽

Robert L. DeWitty Jr.

Keyword(s):

Breast Cancer ◽

Marital Status ◽

Cancer Patients ◽

Proportional Hazards ◽

Breast Cancer Prognosis ◽

Cancer Prognosis ◽

Breast Cancer Patients ◽

Howard University ◽

Kaplan Meier ◽

Seer Data

Breast cancer prognosis is a vital element of providing effective treatment for breast cancer patients. Breast cancer prediction survivability has mainly been studied based on pathological factors such as tumor size, tumor grade, number of positive lymph nodes, and hormone receptors among others. This chapter looks at the significance of the non-clinical prognostic factors of age, ethnicity, and marital status in finding the prognosis for breast cancer patients. The National Cancer Institute's SEER data and the Howard University Cancer Center Tumor Registry data are analyzed. Prognostic tool NPI (Nottingham Prognostic Index) and survival analysis tools of Cox proportional hazards and Kaplan-Meier survival curve are used in analyzing the experiments. The results suggest that age, ethnicity, and marital status have some influence on the survivability rate of breast cancer patients.

Download Full-text

The tumor microbiome is implicated in breast cancer prognosis

10.21203/rs.3.rs-97367/v1 ◽

2020 ◽

Author(s):

Jia Zhu ◽

Jie Wu ◽

Changgan Mo ◽

Siyuan Liang ◽

Tao Lian ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Alpha Diversity ◽

Breast Cancer Prognosis ◽

Cancer Prognosis ◽

Rrna Gene ◽

Breast Cancer Patients ◽

Immune Microenvironment ◽

Tumor Tissues ◽

Tumor Immune Microenvironment

Abstract Background: Some breast cancer patients are prone to recurrence and metastasis. Increasing evidence suggests that the breast tissue contains a diverse population of bacteria, which may be modulating the risk of breast cancer development or progression. However, the extent of microbial contribution to the tumor immune microenvironment in breast cancer remains unknown. Here, we explored the potential influence of the tumor microbiota on the local immune microenvironment and breast cancer prognosis.Methods: Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition and identified bacteria that were differentially abundant between breast cancer patients with recurrence or metastasis (R/M) and those without recurrence or metastasis (NRM). We performed total RNA sequencing in tumor tissues from patients in both groups to determine differentially expressed genes (DEGs). The landscape of tumor-infiltrating immune cells (TIICs) subtypes in the tumor immune microenvironment was analyzed using CIBERSORT, based on the gene expression profiling of tumor tissues. Differences in the tumor microbiomes were then correlated with DEGs and differences in TIICs, in order to determine how microbial abundance may contribute to cancer progression.Results: Microbial alpha-diversity was higher in NRM patients than in R/M patients. The composition and functions of the tumor microbiome communities differed between the two groups. We found higher alpha-diversity, higher abundance of Ruminococcus, Butyrivibrio, and Deinococcus, and lower abundance of Microbacterium could serve as a predictor of better prognosis in breast cancer patients. We also found that 16 genes, including CD36, showed differential expression in NRM compared to R/M, and differences in the composition of TIICs were observed between the two groups. In addition, we observed that the different tumor microbiome profiles were associated with DEGs and differences in TIICs between the two groups.Conclusions: The tumor microbiome may affect the prognosis of breast cancer patients by influencing the tumor immune microenvironment. Thus, the tumor microbiome may be a useful prognostic indicator.

Download Full-text

Utilization and evaluation of noncore chemotherapy regimens within an academic medical center

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155216657679 ◽

2016 ◽

Vol 23 (7) ◽

pp. 518-524 ◽

Cited By ~ 1

Author(s):

Jason R Jared ◽

Mary S Mably ◽

Rory Makielski ◽

Michael P Reed ◽

Michael J Fallon ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Clinical Outcomes ◽

Chemotherapy Regimen ◽

Stage I ◽

Stage Ii ◽

Disease Stage ◽

Patient Specific ◽

Breast Cancer Patients ◽

Specific Factors

Uniformity of evidence-based chemotherapy prescribing using approved, standard, or “core” regimens provides systems-based safety. Noncore chemotherapy regimens are non-standard-of-care regimens requested by physicians on a patient-by-patient basis. Chemotherapy Council, a Pharmacy & Therapeutics subcommittee, assesses all requests and determines approval status based upon submitted evidence and patient-specific factors. This study's purpose is to describe noncore chemotherapy regimens utilization, efficacy, and clinical outcomes in patients receiving noncore chemotherapy regimens. This retrospective chart review includes a two-stage utilization and outcomes evaluation of patients receiving noncore chemotherapy regimens. Stage I, a demographics and utilization assessment of patients receiving noncore chemotherapy regimens, has data collection including patient age, sex, performance score, malignancy, and noncore chemotherapy regimen use justification. Stage II assesses noncore chemotherapy regimen-related, patient-specific outcomes of breast cancer noncore chemotherapy regimen patients. Breast cancer patients were evaluated on regimen and clinical outcomes including disease stage, regimen duration, discontinuation reason, subsequent chemotherapy, survival, and time from noncore chemotherapy regimen until death. Within stage I, 307 patient-specific noncore chemotherapy regimen requests were submitted. The most commonly submitted rationale was modification of a core regimen (33%), followed by patient-specific factors (29%) and salvage therapy (22%). For stage II, 29 breast cancer patients received a noncore chemotherapy regimen and most (54%) received a modified core regimen. The vast majority of noncore chemotherapy regimen discontinuation was due to either regimen completion (42%) or disease progression (42%). Nonelective hospitalizations (35%) and mortality (30%) were found during the median 13.3 months of follow up. Noncore chemotherapy regimen use provides regimen tailoring for patients who are candidates for further therapy, but nonelective hospitalizations, end-of-life chemotherapy, and mortality warrant further investigation to improve patient outcomes.

Download Full-text